Abiraterone Acetate

"Abiraterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Descriptor ID	D000069501
MeSH Number(s)	D04.210.500.054.079.065
Concept/Terms	Abiraterone Acetate Abiraterone Acetate 17-(3-pyridyl)-5,16-androstadien-3beta-acetate 17-(3-pyridyl)-5,16-androstadien-3beta-acetate Zytiga Zytiga CB 7630 CB 7630 CB-7630 CB7630

Below are MeSH descriptors whose meaning is more general than "Abiraterone Acetate".

Chemicals and Drugs [D]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Androstanes [D04.210.500.054]
Androstenes [D04.210.500.054.079]
Abiraterone Acetate [D04.210.500.054.079.065]

Below are MeSH descriptors whose meaning is related to "Abiraterone Acetate".

Below are MeSH descriptors whose meaning is more specific than "Abiraterone Acetate".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Abiraterone Acetate" by people in this website by year, and whether "Abiraterone Acetate" was a major or minor topic of these publications.

Bar chart showing 24 publications over 12 distinct years, with a maximum of 4 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2012	0	1	1
2013	0	1	1
2014	0	1	1
2015	1	1	2
2016	1	2	3
2017	2	2	4
2018	2	0	2
2019	2	0	2
2021	1	2	3
2022	1	1	2
2023	2	0	2
2024	0	1	1

Below are the most recent publications written about "Abiraterone Acetate" by people in Profiles.

Castro E, Wang D, Walsh S, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2025 09; 28(3):817-827.

View in: PubMed
Yu EY, Berry WR, Gurney H, Retz M, Conter HJ, Laguerre B, Fong PCC, Ferrario C, Todenh?fer T, Gravis G, Piulats JM, Emmenegger U, Shore ND, Romano E, Mourey L, Li XT, Poehlein CH, Schloss C, Appleman LJ, de Bono JS. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. Eur Urol Oncol. 2024 06; 7(3):509-518.

View in: PubMed
Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clin Cancer Res. 2023 07 05; 29(13):2426-2434.

View in: PubMed
Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, Cullberg M, Teruel CF, Morris T. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 04; 21(2):278-285.

View in: PubMed
Shah YB, Shaver AL, Kelly WK, Lu-Yao G. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One. 2022; 17(8):e0273826.

View in: PubMed
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandstr?m P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022 Jan; 18(1):35-45.

View in: PubMed
Shore ND, Ionescu-Ittu R, Lalibert? F, Yang L, Lejeune D, Yu L, Duh MS, Mahendran M, Kim J, Ghate SR. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer. 2021 12; 19(6):480-490.

View in: PubMed
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 05; 81(7):418-426.

View in: PubMed
Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, Gomella L, Kelly WK. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol. 2020 02; 77(2):158-166.

View in: PubMed
Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, Wong YN, Pei H, McGowan T. Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). Clin Genitourin Cancer. 2019 12; 17(6):457-463.e6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement